ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2
89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)
Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR
#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting